Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

PURPOSE: Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated. PATIENT...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Piekarz, Richard L., Frye, Robin, Turner, Maria, Wright, John J., Allen, Steven L., Kirschbaum, Mark H., Zain, Jasmine, Prince, H. Miles, Leonard, John P., Geskin, Larisa J., Reeder, Craig, Joske, David, Figg, William D., Gardner, Erin R., Steinberg, Seth M., Jaffe, Elaine S., Stetler-Stevenson, Maryalice, Lade, Stephen, Fojo, A. Tito, Bates, Susan E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2009
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2773225/
https://ncbi.nlm.nih.gov/pubmed/19826128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.6150
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller